What is the difference between Type 1 and Type 3 gastric neuroendocrine tumors (gastric carcinoids)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Type 1 gastric carcinoids should be managed with endoscopic resection for lesions less than 1-2 cm, while type 3 gastric carcinoids require more aggressive treatment, usually involving surgical resection with lymph node dissection, due to their high metastatic potential and poor prognosis. The management of type 1 and type 3 gastric carcinoids differs significantly due to their distinct pathophysiology and prognosis. Type 1 gastric carcinoids are the most common type, accounting for 70-80% of cases, and are associated with chronic atrophic gastritis and hypergastrinemia 1. They typically present as small, multiple polyps in the gastric fundus or body, are usually well-differentiated, and have a low metastatic potential (less than 5%) 1. In contrast, type 3 gastric carcinoids are sporadic tumors not associated with hypergastrinemia or other conditions, are typically solitary, larger lesions, and are more aggressive with a high metastatic potential (50-100%) 1.

The prognosis for type 1 gastric carcinoids is generally excellent with a 5-year survival rate exceeding 95%, while type 3 has a much poorer prognosis with 5-year survival rates of 25-30% 1. The distinction between these types is crucial for determining appropriate treatment and follow-up strategies. According to the most recent guidelines, individuals with type 1 gastric carcinoids >2 cm should undergo cross-sectional imaging and be referred for surgical resection, given the risk of metastasis 1. On the other hand, type 3 gastric carcinoids require radical resection of the tumor with regional lymphadenectomy, regardless of size 1.

Key differences between type 1 and type 3 gastric carcinoids include:

  • Pathophysiology: Type 1 is associated with chronic atrophic gastritis and hypergastrinemia, while type 3 is sporadic and not associated with any underlying condition 1.
  • Prognosis: Type 1 has a low metastatic potential and excellent prognosis, while type 3 has a high metastatic potential and poor prognosis 1.
  • Management: Type 1 can be managed with endoscopic resection for lesions less than 1-2 cm, while type 3 requires surgical resection with lymph node dissection 1.
  • Treatment outcomes: Type 1 has a high 5-year survival rate, while type 3 has a lower 5-year survival rate 1.

In summary, the management of type 1 and type 3 gastric carcinoids should be tailored to their distinct pathophysiology, prognosis, and treatment outcomes, with a focus on minimizing morbidity, mortality, and improving quality of life 1.

From the Research

Type 1 Gastric Carcinoid

  • Type 1 gastric carcinoids (TIGCs) are related to chronic atrophic gastritis and are characterized by hypergastrinemia and hyperplasia of enterochromaffin-like cells 2
  • TIGCs are the most frequently diagnosed of all gastric carcinoids, accounting for about 70-80% 2, 3
  • Endoscopically, TIGCs are present as small (<10 mm), polypoid lesions or, more frequently, as smooth, rounded submucosal lesions 2
  • Most TIGCs are well-differentiated tumors, with metastasis being rare, and patients with TIGCs generally have an excellent prognosis 2, 4
  • Treatment options for TIGCs include total gastrectomy, partial resection, antrectomy, endoscopic resection, and endoscopic surveillance 2, 4

Type 3 Gastric Carcinoid

  • Type 3 gastric carcinoids represent 15-25% of gastric carcinoids and are characterized by a far more aggressive course 3
  • Type 3 gastric carcinoids are not associated with chronic atrophic gastritis or hypergastrinemia, and have a higher metastatic potential compared to type 1 gastric carcinoids 3
  • The optimal clinical approach to type 3 gastric carcinoids remains to be elucidated, but surgical treatment is often recommended due to their aggressive nature 3

Comparison of Type 1 and Type 3 Gastric Carcinoids

  • Type 1 gastric carcinoids are generally benign and have a low metastatic potential, whereas type 3 gastric carcinoids are more aggressive and have a higher metastatic potential 3, 5
  • Treatment options for type 1 gastric carcinoids include endoscopic surveillance, endoscopic resection, and surgical resection, whereas type 3 gastric carcinoids often require surgical treatment due to their aggressive nature 2, 3, 4
  • The prognosis of type 1 gastric carcinoid patients is generally favorable, with a high recurrence-free survival and disease-specific survival rate, whereas the prognosis of type 3 gastric carcinoid patients is often poorer due to their aggressive nature 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical features and management of type I gastric carcinoids.

Clinical journal of gastroenterology, 2014

Research

Current concepts on gastric carcinoid tumors.

Gastroenterology research and practice, 2012

Research

Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan.

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 2014

Research

Unusually aggressive type 1 gastric carcinoid: a case report with a review of the literature.

European journal of gastroenterology & hepatology, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.